Tharimmune reports pharmacokinetic simulation results for th104 as prophylaxis against respiratory depression from fentanyl and ultrapotent opioids, highlighting potential superiority over existing treatments

Red bank, nj / access newswire / august 20, 2025 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and unmet medical needs announced positive results from a recent pharmacokinetic (pk) simulation analysis of its lead clinical asset, th104, a buccal film formulation of nalmefene. the results reinforce the potential of th104 as a prophylactic countermeasure for military personnel and chemical incident responders who may be exposed to high-potency opioids, including weaponized fentanyl and its analogues.
THAR Ratings Summary
THAR Quant Ranking